The latest price target for HLS Therapeutics (OTCPK:HLTRF) was reported by Raymond James on March 18, 2024. The analyst firm set a price target for $5.00 expecting HLTRF to rise to within 12 months (a possible 109.64% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for HLS Therapeutics (OTCPK:HLTRF) was provided by Raymond James, and HLS Therapeutics maintained their market perform rating.

There is no last upgrade for HLS Therapeutics

There is no last downgrade for HLS Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HLS Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HLS Therapeutics was filed on March 18, 2024 so you should expect the next rating to be made available sometime around March 18, 2025.

While ratings are subjective and will change, the latest HLS Therapeutics (HLTRF) rating was a maintained with a price target of $6.50 to $5.00. The current price HLS Therapeutics (HLTRF) is trading at is $2.38, which is out of the analyst’s predicted range.